The Royal Marsden NHS Foundation Trust
Buyer information published with procurement notices.
- Published identifier
- GB-PPON PXLT-9823-WVCY
- Address
- London, UKI33, SW3 6JJ, United Kingdom
- First notice
- 6 May 2025
- Latest notice
- 21 Sept 2026
Published procurement activity · 24 tenders
Buyer information published with procurement notices.
Provision of CT Radiopharmaceuticals -Nanotop, MAG3, Tektrotyd, Illuccix
Provision 2 x ELITe BeGenius ACE PCR analysers and bring testing in house
Provision of Radiopharmaceuticals
the supply of FDG tracers used for PET-CT's in privately funded patients and research.
The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and serv
Provision of independent Lifts Authorising Engineer services, including statutory compliance assurance, technical advice, inspection oversight, certification review, and support to ensure safe operation and compliance with relevant legislation and standards across the Trust’s estate.
Contract for Netspot Kits required by the trust
The Royal Marsden is currently exploring alternative operating models for its microbiology services and is undertaking a market engagement exercise to gather insights from providers. The exercise is designed to be a fact-finding and there is no formal evaluation. Providers are encouraged to propose individual solutions on their
The Laboratory at RMH is currently using these DNA adaptors for high throughput sequencing experiments. These reagents are required to deliver a service. The adaptors have been validated for tests that RMH offers as part of the Molecular Diagnostic service and are incorporated into Standard Operating Procedures.
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team
Organisation details and tender classifications reflect information published by the original procurement sources. Similar buyer names are grouped only where an official identifier or compatible name and postcode provide a safe link.